ISCT 2021 | Addressing the unproven cell-based therapy market

Miguel Forte, MD, PhD, Bone Therapeutics SA, Gosselies, Belgium, suggests how the cell and gene therapy industry can help to address the unproven cell-based therapy market. He highlights that strong evidence-based research is required to determine whether the benefits of a particular cell-based therapy outweigh the risks before they are used in patients. Additionally, the education of patients and stakeholders is required to improve understanding of how products are developed, which products have been proven to be safe and effective and how they should be used. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.